Genomic Predictors of Recurrent Pregnancy Loss

Launched by YALE UNIVERSITY · Jun 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the genetic factors that may contribute to recurrent pregnancy loss (RPL), which is when a woman experiences multiple miscarriages. The goal is to identify specific genetic markers that could help predict the risk of RPL, potentially leading to better prevention and treatment options in the future. The trial is currently recruiting participants and is open to women aged 18 to 62 who have had a recent singleton pregnancy loss before 20 weeks of gestation, along with one or more previous pregnancy losses.

To participate, women must meet certain criteria, such as having a normal genetic makeup for their current pregnancy and no history of specific health issues like autoimmune diseases or uterine problems. If eligible, participants can expect to undergo genetic testing and contribute valuable information that could help researchers understand RPL better. This study aims to provide insights that may one day assist women experiencing recurrent pregnancy loss in having healthier pregnancies.

Gender

ALL

Eligibility criteria

• • 1. Women with loss of a current singleton pregnancy at \< 20 0/7 weeks gestation (documented by ultrasonography or histopathological examination) and one or more prior pregnancy losses.
• • 2. Euploid current pregnancy by karyotype or microarray (a limited number of aneuploid losses will be included as part of the pilot)
• • 3. No history of parental karyotype abnormalities
• • 4. No history of antiphospholipid antibody syndrome
• • 5. No evidence of uncontrolled diabetes
• • 6. No evidence of uncontrolled thyroid disease
• • 7. No history of autoimmune disease (SLE, RA)
• • 8. No history of uterine anomalies
• • 9. No history of cervical insufficiency